Development and Validation of a New RP-HPLC Analytical Method for the Simultaneous Determination of Luliconazole and Clobetasol Propionate in Synthetic Mixture

Binal Solanki *

Nootan Pharmacy College, Sankalchand Patel University, Visnagar, India. Laxminarayan Dev College of pharmacy, Bharuch India.

Hirak Joshi

Faculty of Pharmacy, Nootan Pharmacy College, Sankalchand Patel University, Visnagar. India.

*Author to whom correspondence should be addressed.


Abstract

Aim: To develop new selective and sensitive reverse-phase high-performance liquid chromatography (RP-HPLC) approach for the quantification of antifungal drug Luliconazole integrate with corticosteroid drug Clobetasol Propionate in a synthetic mixture.

Methods: The method was validated to achieve International Conference Harmonization (ICH) requirements. Chromatographic separation was carried out by isocratic technique on a reversed-phase Inertsil C18 column (5 µm, 250mm x 4.6mm i.d with the mixture of Acetonitrile: Water pH adjusted with H3PO4 (60: 40) and UV detection at 264 nm. The compounds were eluted at a flow rate of 1.0 mL/min with an injection volume of 20μL.

Results: The calibration curves were linear (r2 > 0.999) over the concentration range 10-200 μg/mLfor Luliconazole and 5-100 μg/mL for Clobetasol Propionate. The average retention times for Luliconazole and Clobetasol Propionate were 3.16 and 6.94 min, respectively. The % RSD   for the proposed method was found to be less than %2. The % recovery was found to between 99.22-99.48% for the developed method.

Conclusion: The developed method is simple, rapid, precise, and accurate and hence was successfully applied for the determination of Luliconazole and Clobetasol Propionate in a synthetic mixture.

Keywords: Antifungal drug, analytical method, glucocorticoids, validation


How to Cite

Solanki, B. and Joshi, H. (2021) “Development and Validation of a New RP-HPLC Analytical Method for the Simultaneous Determination of Luliconazole and Clobetasol Propionate in Synthetic Mixture”, Journal of Pharmaceutical Research International, 33(32B), pp. 53–60. doi: 10.9734/jpri/2021/v33i32B31742.